<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="59152">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335944</url>
  </required_header>
  <id_info>
    <org_study_id>CINC280X2105C</org_study_id>
    <secondary_id>2014-000726-37</secondary_id>
    <nct_id>NCT02335944</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy of EGF816 in Combination With INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation.</brief_title>
  <official_title>A Phase Ib/II, Multicenter, Open-label Study of EGF816 in Combination With INC280 in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study determines the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of
      EGF816 in combination with INC280 and to estimate the preliminary anti-tumor activity of
      EGF816 in combination with INC280 in patients with advanced non-small cell lung cancer
      (NSCLC) with documented EGFR mutation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2015</start_date>
  <completion_date type="Anticipated">June 3, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 3, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Ib : Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>First 28 days of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II : objective response rate per RECIST v1.1</measure>
    <time_frame>When all patients have completed at least 6 cycles of treatment or discontinued prior to that time for any reason.</time_frame>
    <description>1 cycle = 28 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>From baseline until 30 days post study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of INC280 and EGF816</measure>
    <time_frame>continuously during study until 30 days after post study treatment</time_frame>
    <description>Safety by looking at hematology and chemistry values, vital signs and electrocardiograms (ECGs). 1 cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of dose interruption, frequency of reduction and dose intensity</measure>
    <time_frame>Day 1 of each cycle</time_frame>
    <description>1 cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate (phase Ib only)</measure>
    <time_frame>baseline, every 8 weeks until disease progression, consent withdraw or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>baseline, every 8 weeks until disease progression, consent withdraw or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>baseline, every 8 weeks until disease progression, consent withdraw or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>baseline, every 8 weeks until disease progression, consent withdraw or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>start of treatment until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma concentration versus time profiles</measure>
    <time_frame>Cycle 1 : Day 1, Day 2, Day 8, Day 15 and Day 16, Cycle 2 : Day 1 and Day 2, Cycle 3 Day 1 and Cycle 4 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of EGF816</measure>
    <time_frame>Cycle 1 : Day 1, Day 2, Day 8, Day 15 and Day 16, Cycle 2 : Day 1 and Day 2, Cycle 3 Day 1 and Cycle 4 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of INC280</measure>
    <time_frame>Cycle 1 : Day 1, Day 2, Day 8, Day 15 and Day 16, Cycle 2 : Day 1 and Day 2, Cycle 3 Day 1 and Cycle 4 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) of INC280</measure>
    <time_frame>Cycle 1 : Day 1, Day 2, Day 8, Day 15 and Day 16, Cycle 2 : Day 1 and Day 2, Cycle 3 Day 1 and Cycle 4 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) of EGF816</measure>
    <time_frame>Cycle 1 : Day 1, Day 2, Day 8, Day 15 and Day 16, Cycle 2 : Day 1 and Day 2, Cycle 3 Day 1 and Cycle 4 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half life (t1/2) of INC280</measure>
    <time_frame>Cycle 1 : Day 1, Day 2, Day 8, Day 15 and Day 16, Cycle 2 : Day 1 and Day 2, Cycle 3 Day 1 and Cycle 4 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half life (t1/2) of EGF816</measure>
    <time_frame>Cycle 1 : Day 1, Day 2, Day 8, Day 15 and Day 16, Cycle 2 : Day 1 and Day 2, Cycle 3 Day 1 and Cycle 4 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to response</measure>
    <time_frame>baseline, every 8 weeks until disease progression, consent withdraw or death</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>INC280 plus EGF816</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INC280</intervention_name>
    <arm_group_label>INC280 plus EGF816</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGF816</intervention_name>
    <arm_group_label>INC280 plus EGF816</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with histologically documented, locally advanced or recurrent (stage IIIB
             who are not eligible for combined modality treatment) or metastatic (Stage IV)
             non-small cell lung cancer

          -  Patients must have locally documented EGFR mutation L858R and/or ex19del, or a
             characterized de novo EGFR T790M mutation (or other rare activating mutations that
             confer sensitivity to first and second generation EGFR inhibitors (e.g. L861Q, G719X,
             S768I)

          -  Presence of at least one measurable lesion according to RECIST v.1.1

          -  ECOG performance status ≤1

          -  Patients must be screened for HBV. Patients who are either HBsAg positive or HBV-DNA
             positive must be willing and able to take antiviral therapy 1-2 weeks prior to 1st
             dose of EGF816 treatment and continue on antiviral therapy for at least 4 weeks after
             the last dose of EGF816. Additional management of the patients would be provided by a
             physician with expertise in management of HBV, if needed.

          -  Patients must be screened for HCV. Patients must have negative hepatitis C antibody
             (HCV Ab) or are HCV Ab positive but with an undetectable level of HCV-RNA. Note:
             patients with detectable HCV-RNA are not eligible for the study.

          -  Phase Ib only: documented progression of disease according to RECIST v1.1 while on
             continuous treatment with EGFR TKI (erlotinib, gefitinib or afatinib).

          -  Phase II Group 1 (EGFRmut, any T790M, any c-MET, 2/4L antineoplastic, EGFR TKI
             resistant) only: Patients demonstrated a documented clinical benefit (CR (any
             duration), PR (any duration), or SD for at least 6 months) on prior EGFR TKI (e.g.
             erlotinib, gefitinib or afatinib, and subsequently demonstrated progression according
             to RECIST v1.1.

          -  Phase II Group 2 (EGFRmut, de novo T790M, any c-MET, 1/3L antineoplastic, EGFR TKI
             naïve) only: Advanced NSCLC patients who have not been previously treated with any
             therapy known to inhibit EGFR and harbor de novo T790M mutation .

          -  Phase II Group 3 (EGFRmut, T790M negative, any c-MET, 1L antineoplastic) only:
             patients must harbor an EGFR activating mutation and must be naïve from any line of
             systemic antineoplastic therapy in the advanced setting.

        Exclusion Criteria:

          -  Phase Ib:

               -  More than one previous treatment line with erlotinib, gefitinib or afatinib

               -  Previous treatment with any investigational agent known to inhibit EGFR (mutant
                  or wild-type)

               -  Patients who have received more than three prior lines of antineoplastic
                  therapies (including EGFR TKI) in advanced setting.

          -  Phase II Group 1 (EGFRmut, any T790M, any c-MET, 2/4L antineoplastic, EGFR TKI
             resistant):

               -  More than 3 prior lines of systemic antineoplastic therapies (including EGFR
                  TKI) in the advanced setting

               -  More than 1 previous treatment line with 1st or 2nd generation EGFR TKI (e.g.
                  erlotinib, gefitinib, afatinib) in the advanced setting

               -  Previous treatment with an investigational or marketed 3rd generation EGFR TKI
                  (e.g. AZD9291, CO-1686, ASP8273, EGF816)

               -  Previous treatment with an investigational or marketed agent known to inhibit
                  EGFR (e.g. EGF monoclonal antibody therapy, dual TKI inhibitor).

          -  Phase II Group 2 (EGFRmut, de novo T790M, any c-MET, 1/3L antineoplastic, EGFR TKI
             naïve):

               -  More than two previous treatment lines of systemic antineoplastic therapies in
                  the advanced setting

               -  Previous treatment with an investigational or marketed agent that inhibits EGFR.
                  EGFR inhibitors include (but not limited to) all generations of EGFR TKI
                  (e.g.erlotinib, gefitinib, afatinib, AZD9291, CO-1686, ASP8273, EGF816) or other
                  anti-EGFR or EGFR monoclonal antibody therapy or dual TKI inhibitors.

          -  Phase II Group 3 (EGFRmut, T790M negative, any c-MET, 1L antineoplastic):

               -  De novo EGFR T790M mutation identified by central assessment

               -  Previous treatment with any systemic antineoplastic therapy in the advanced
                  setting (NSCLC stage IIIB or IV. Patients who received only one cycle of
                  chemotherapy in the advanced setting are allowed).

          -  Previous treatment with a c-MET inhibitor or HGF-targeting therapy.

          -  Patients with brain metastases. However, patients with controlled brain metastases
             may participate in the trial. These patients must have completed any radiation
             therapy and/or surgery &gt; 2 weeks prior to the first dose of study treatment and
             remain asymptomatic.

          -  History of another malignancy. Exception: Patients who have been disease-free for 3
             years, or patients with a history of adequately treated in-situ carcinoma of the
             uterine cervix, basal or squamous cell carcinoma, non-melanomatous cancer of skin,
             history of stage IA melanoma that has been cured, are eligible.

          -  Undergone a bone marrow or solid organ transplant.

          -  Known history of human immunodeficiency virus (HIV) seropositivity (HIV testing is
             not mandatory)

          -  Patients receiving concomitant immunosuppressive agents or chronic corticosteroids
             use at the time of study entry except for control of brain metastases, topical
             applications, inhaled sprays, eye drops or local injections

          -  Patients with clinically significant, uncontrolled cardiovascular disease

          -  Presence or history of interstitial lung disease or interstitial pneumonitis

          -  Patients have not recovered from all toxicities related to prior anticancer therapies
             to grade ≤1 (CTCAE v 4.03)

          -  Patients have out of range laboratory values defined as

               1. Absolute Neutrophil Count (ANC) &lt;1.5 x 109/L (1.5x103/µL)

               2. Hemoglobin (Hb) &lt;9 g/dL (90g/L)

               3. Platelets (PLT) &lt;75 x 109/L (75x103/µL)

               4. Total bilirubin &gt;1.5 x upper limit of normal (ULN).

               5. AST and/or ALT &gt;3 x ULN

               6. Patients with liver metastasis may not be included if AST and/or ALT &gt;5 xULN

               7. Alkaline phosphatase (ALP) &gt;5 xULN

               8. Calculated creatinine clearance &lt; 45mL/min (0.75 mL/sec)using Cockroft-Gault
                  formula

               9. Asymptomatic serum amylase and lipase &gt; Grade 2

              10. Serum amylase or serum lipase CTCAE grade ≥ 1 with signs and/or symptoms
                  suggesting pancreatitis or pancreatic injury (e.g. elevated P-amylase, abnormal
                  imaging findings of pancreas, etc)

          -  Patients have the following laboratory values outside of the laboratory normal limits
             or cannot be corrected to within normal limits with supplements during screening:
             Potassium, Magnesium, Phosphorus, Total calcium (corrected for serum albumin)

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute H Lee Moffitt</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Melendez</last_name>
      <phone>813-745-6895</phone>
      <email>michael.melendez@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Eric B. Haura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Mass General</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lecia Sequist</last_name>
      <phone>617-724-4000</phone>
    </contact>
    <contact_backup>
      <last_name>Beth Kennedy</last_name>
      <phone>+1 617 724 1223</phone>
      <email>EAKENNEDY@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lecia Sequist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille cedex 05</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perugia</city>
        <state>PG</state>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>NO-0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Coruna</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <state>Taiwan ROC</state>
        <zip>10041</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Norway</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 1, 2017</lastchanged_date>
  <firstreceived_date>October 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non small cell lung cancer,</keyword>
  <keyword>NSCLC,</keyword>
  <keyword>EGF816,</keyword>
  <keyword>INC280,</keyword>
  <keyword>tyrosine kinase inhibitor,</keyword>
  <keyword>c-MET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
